Daxor (NASDAQ:DXR) Trading Up 6.7% – Here’s Why

Daxor Corporation (NASDAQ:DXR) shot up 6.7% during mid-day trading on Tuesday . The company traded as high as $10.41 and last traded at $10.14. Approximately 2,812 shares were traded during trading, an increase of 30% from the average daily volume of 2,162 shares. The stock had previously closed at $9.50.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “hold (c)” rating on shares of Daxor in a research note on Friday, March 27th. One analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy”.

Daxor Stock Up 6.7%

The firm’s fifty day simple moving average is $10.28 and its 200-day simple moving average is $11.52.

Daxor (NASDAQ:DXR) last posted its quarterly earnings results on Monday, March 2nd. The company reported ($0.10) EPS for the quarter.

Hedge Funds Weigh In On Daxor

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Aristides Capital LLC purchased a new stake in Daxor during the 1st quarter valued at $403,000. Crescent Grove Advisors LLC bought a new stake in shares of Daxor in the 1st quarter worth $104,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management purchased a new position in shares of Daxor in the first quarter worth $245,000. Nano Cap New Millennium Growth Fund L P purchased a new position in shares of Daxor in the fourth quarter worth $184,000. Finally, Osaic Holdings Inc. bought a new position in shares of Daxor during the second quarter valued at $86,000. 1.34% of the stock is owned by institutional investors.

About Daxor

Daxor Corporation is a medical diagnostics company focused on providing precise blood volume analysis to support patient management in critical care, surgical, cardiology and nephrology settings. The company’s core offering, the BVA‐100 Blood Volume Analyzer, employs radiolabeled albumin techniques to deliver accurate measurements of total blood volume, red cell mass and plasma volume. By quantifying a patient’s fluid status, Daxor aims to help clinicians tailor therapies for conditions such as anemia, heart failure and fluid overload.

In addition to the BVA‐100 analyzer, Daxor supplies reagent kits, calibration standards and software for data analysis and reporting.